TLSA Reports Positive Clinical Data for Intranasal Foralumab, 64% of Patients Show Clinically Meaningful Fatigue Improvement, Favorable EDSS Stabilization Trend
Tiziana Life Sciences Ltd. Common Shares · Now $1.41
+17% in 1d after detection
Post-detection moves
1h
—
1d
+17%
3d
+7.2%
7d
+2.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS